Mark J. Holterman, Medical

A Look at Some Early Indicators of Autoimmunity


Autoimmunity pic

A former National Merit Scholar at Yale University, Mark Holterman, MD leverages decades of clinical experience as a professor of surgery and pediatrics at the University of Illinois College of Medicine in Peoria, Illinois. Also a researcher, Dr. Mark Holterman holds a particular interest in regenerative medicine, stem cell therapies, obesity, innovative cancer treatments, and autoimmunity.

Autoimmunity refers to a condition in which the body’s immune system begins to attack the body itself. Some form of autoimmunity is present in everyone, but when serious it can lead to a range of autoimmune diseases that include type 1 diabetes, multiple sclerosis, and lupus. Although it is not known what causes autoimmune disease, genetic history, infections, diet, and chemical exposure are all thought to play a role.

Many autoimmune disorders have unique symptoms. However, the early symptoms are often quite similar. In addition to fatigue and muscle aches, individuals with autoimmune disorders may experience swelling, inflammation, and a fever. Hair loss, hand and foot numbness, and rashes on the skin may also be present. Lastly, autoimmune disorders often make it difficult for individuals to concentrate.

Mark J. Holterman, Medical

About the 2018 AACA Annual Meeting


American Association of Clinical Anatomists pic
American Association of Clinical Anatomists

An accomplished pediatric surgeon with upwards of three decades of experience in the field, Mark Holterman, MD, serves as a faculty member at the University of Illinois College of Medicine. An active member of a number of professional organizations, Dr. Mark Holterman belongs to the American Association Of Clinical Anatomists (AACA).

The AACA will hold its 35th Annual conference on July 8-12, 2018 at the Grand Hyatt Buckhead in Atlanta, Georgia. Hosted by the Morehouse School of Medicine, the event will feature keynote speakers and breakout sessions geared toward arming attendees with the latest advances and information in the field of clinical anatomy.

Lodging for the conference will be available on-site at the Grand Hyatt and shuttle options will be available from the Hartsfield-Jackson International Airport to the hotel for those traveling by plane to the conference. To learn more about the meeting or register, visit

Mark J. Holterman, Medical

ADA Praises Congress for Funding Special Diabetes Program


Research Awards pic
American Diabetes Association

With three decades of experience as a physician and an educator, Mark Holterman, MD, serves as a professor of medicine at the University of Illinois College of Medicine. In addition to his work as an educator, Dr. Mark Holterman engages with such organizations as the American Diabetes Association (ADA).

The ADA recently praised the federal government for agreeing to fund the Special Diabetes Program (SDP) to the tune of $600 million. SDP is one of the major drivers of research into type 1 diabetes and how to prevent type 2 diabetes for American Indians across the country. Thanks to this new funding, researchers will be able to continue exploring new treatments for diabetes in these communities, which are at exceptionally high risk of developing the disease.

The ADA recognized the Diabetes Caucuses in both houses of Congress for their work in helping this funding package come to fruition. The organization says it will continue to work with lawmakers to ensure that programs such as SDP continue to receive the support they need.

Mark J. Holterman, Medical

The Potential of Regenerative Medicine to Restore Organ Function


Dr. Mark J. Holterman pic
Dr. Mark J. Holterman

Dr. Mark Holterman, a longtime advocate of regenerative medicine and stem cell therapy, serves as pediatrics professor at the University of Illinois College of Medicine in Peoria. Reflecting decades of research employing ethically sourced fetal stem cells, Mark J. Holterman, MD, seeks to promote the academic study of the safety and efficacy of innovative treatment modalities.

An emerging area of medical science, regenerative medicine at its foundation centers on restoring the functionality of organs and tissues, specifically those that have been damaged or are associated with chronic disease and severe injuries that do not respond to conventional therapies. Restoration of function is enabled through a combination of tissue engineering and gene editing advancements, which allows stem cells to be remodeled as three-dimensional tissue structures and organoids that meet highly specific needs.

Enabling this is the potentially limitless ability of stem cells to divide and transdifferentiate into a variety of cell types. As such, stem cells provide a foundation for the body’s full range of organs and tissues. Employing microengineering and cell transplantation techniques, organoids are grown that have the potential to take the place of donated organs and tissues, which are of limited supply and expensive.

Mark J. Holterman, Medical

Cellular Therapy FAQs


Alliance for the Advancement of Cellular Therapies pic
Alliance for the Advancement of Cellular Therapies

Mark Holterman, MD, PhD, teaches surgery and pediatrics at the University of Illinois College of Medicine. As a cofounder of the Alliance for the Advancement of Cellular Therapies (AACT), Dr. Mark Holterman promotes the safe and ethical advancement of regenerative medicine and stem-cell therapies. The following addresses some frequently asked questions about cellular therapies.

Q: What are cellular therapies?

A: Cellular therapy (CT) entails transplanting human cells to enhance the body’s ability to fight disease and restore tissue and cells. When the body is injured, its adult stem cells activate, traveling to the site of the injury and giving signals to start the healing process. With age, the number of these cells decreases. However, with CT, stem cells are taken from bone marrow or fat and implanted at the injured or diseased site when there is an inadequate supply.

Q: For what diseases can cellular therapies be used?

A: Some diseases that cellular therapies may be used for are osteoarthritis and joint pain, autoimmune disorders, alopecia, and psoriasis.

Q: Are cellular therapies ethical?

A: There are no ethical issues involved in adult stem-cell therapy since they are not embryonic stem cells.

Mark J. Holterman, Medical

CellR4 – Journal for Cellular Therapies



A pediatrics and surgical professor at the University of Illinois College of Medicine, Mark Holterman, MD, holds board positions with multiple medical organizations. Dr. Mark Holterman also is a cofounder of the Alliance for the Advancement of Cellular Therapies (AACT) and serves on its executive board. The AACT collaborates with the CellR4 medical journal to publish research presented at AACT conferences.

The official journal of the Cure Alliance, CellR4 focuses on studies and medical knowledge regarding cellular repair, regeneration, reprogramming, and differentiation. The journal facilitates discussion on challenges and opportunities involved in developing new treatments. Published content includes information on fundamental new discoveries in basic science and the delivery of innovative therapies to transitional and clinical trials. Additionally, CellR4 shares information on global collaborative efforts and features commentaries and opinion papers on legal, ethical, and regulatory issues.

CellR4’s articles are available for full download at no charge on its website.

Mark J. Holterman, Medical

Research Awards at the American Diabetes Association


Research Awards pic
Research Awards

Mark Holterman, MD, has worked for more than two decades building a career as an accomplished researcher and medical practitioner. Before taking on his current role as professor of surgery and pediatrics at the University of Illinois College of Medicine, Dr. Mark Holterman received the Innovative Research Award from the American Diabetes Association  (ADA).

Over the last six decades, ADA has supported nearly 5,000 research initiatives in the field of diabetes through grant funding and dedicated research programming. The Core Research Program is one such avenue through which the organization supports diabetes researchers. In 2017, ADA recognized groundbreaking study in this field with its two Innovative Research Awards.

ADA’s Innovative Basic Science (IBS) Award helps fund work in the field of diabetes etiology and the challenges it poses to treatment efforts. The award gives special consideration to those researchers who are either working on early-stage studies or are poised to make great impact with their work. At the most, the IBS Award provides $115,000 in funding each year for a maximum of three years.

Another Core Program award is the Innovative Clinical or Translational Science (ICTS) Grant, which can supply faculty researchers with up to $200,000 in annual funding over a three-year period. This award focuses primarily on researchers who have applied their medical theories in clinical applications that use humans as research subjects.